EMA's safety committee recommends suspending preterm birth drugs
The European Medicines Agency is taking aim at preterm birth drugs, with the agency’s safety committee recommending that medicines containing 17-hydroxyprogesterone caproate, also known as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.